Processa Pharmaceuticals
PCSA on Nasdaq. Market value $5m.
Should I look at this?
Look carefully before going further
Why it could be worth it
Nothing stands out yet.
What to watch out for
Read the warning sign in its own filings
This is not advice.
Who owns it
None of the long-term investors we follow own it. 12 funds in all.
Largest holders overall
- Connective Capital Management$163,726Added
- Stonepine Capital Management$105,600
- Geode Capital Management$42,412Cut
- Citadel Advisors$40,908New
- StoneX Group$29,623New
- XTX Topco$25,521New
- Jane Street Group$25,466New
- Vanguard Capital Management$24,440
- Vanguard Fiduciary Trust$20,845
- UBS Group AG$14,964Added
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
6 investors own more than 5%.
- HX Entertainment LtdStrategic holder13.0%+2.1 ptsSince 13 February 2026
What they said
No material change from Amendment number one. The additional investment is consistent with The Chiliz Group's previously disclosed investment purpose and strategic interest in the Issuer.
Read the filing - Mitchell P. KopinPassive investorat least 8.1%−1.9 pts(filed with 2 related holders)Since 31 December 2025
- CVI Investments, Inc.Passive investorat least 7.0%−2.0 pts(filed with 1 related holder)Since 31 March 2026
- Soleus Capital Master Fund, L.P.Passive investorat least 5.8%(filed with 5 related holders)Since 3 August 2026
- Armistice Capital, LLCPassive investorat least 5.0%−5.0 pts(filed with 1 related holder)Since 30 June 2025
- 3i, LPPassive investorat least 4.9%(filed with 2 related holders)Since 17 June 2025
| Holder | Stake | Since | |
|---|---|---|---|
HX Entertainment Ltd Strategic holder | 13.0%+2.1 pts | 13 February 2026 | What they saidNo material change from Amendment number one. The additional investment is consistent with The Chiliz Group's previously disclosed investment purpose and strategic interest in the Issuer. Read the filing |
Mitchell P. Kopin Passive investor | at least 8.1%−1.9 pts (filed with 2 related holders) | 31 December 2025 | |
CVI Investments, Inc. Passive investor | at least 7.0%−2.0 pts (filed with 1 related holder) | 31 March 2026 | |
Soleus Capital Master Fund, L.P. Passive investor | at least 5.8% (filed with 5 related holders) | 3 August 2026 | |
Armistice Capital, LLC Passive investor | at least 5.0%−5.0 pts (filed with 1 related holder) | 30 June 2025 | |
3i, LP Passive investor | at least 4.9% (filed with 2 related holders) | 17 June 2025 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 9 insiders bought $208,723 of shares on the open market.
- Ng George KChief Executive Officer, DirectorBought
- Date
- 1 July 2026
- Shares
- 3,057
- Price
- $1.93
- Value
- $5,900
- Guy WendyChief Administrative OfficerBought
- Date
- 30 June 2026
- Shares
- 2,436
- Price
- $1.93
- Value
- $4,701
- Lin PatrickChief Business - Strategy OffBought
- Date
- 30 June 2026
- Shares
- 2,106
- Price
- $1.93
- Value
- $4,065
- SKIBSTED RUSSELLChief Financial OfficerBought
- Date
- 30 June 2026
- Shares
- 3,277
- Price
- $1.93
- Value
- $6,325
- Young DavidPres. Research & Development, DirectorBought
- Date
- 30 June 2026
- Shares
- 2,531
- Price
- $1.93
- Value
- $4,885
- Young DavidPres. Research & Development, DirectorBought
- Date
- 15 June 2026
- Shares
- 2,067
- Price
- $2.22
- Value
- $4,589
- SKIBSTED RUSSELLChief Financial OfficerBought
- Date
- 15 June 2026
- Shares
- 2,654
- Price
- $2.22
- Value
- $5,892
- Ng George KChief Executive Officer, DirectorBought
- Date
- 15 June 2026
- Shares
- 2,465
- Price
- $2.22
- Value
- $5,472
- Lin PatrickChief Business - Strategy OffBought
- Date
- 15 June 2026
- Shares
- 1,831
- Price
- $2.22
- Value
- $4,065
- Guy WendyChief Administrative OfficerBought
- Date
- 15 June 2026
- Shares
- 2,118
- Price
- $2.22
- Value
- $4,702
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 1 July 2026 | Ng George K Chief Executive Officer, Director | Bought | 3,057 | $1.93 | $5,900 |
| 30 June 2026 | Guy Wendy Chief Administrative Officer | Bought | 2,436 | $1.93 | $4,701 |
| 30 June 2026 | Lin Patrick Chief Business - Strategy Off | Bought | 2,106 | $1.93 | $4,065 |
| 30 June 2026 | SKIBSTED RUSSELL Chief Financial Officer | Bought | 3,277 | $1.93 | $6,325 |
| 30 June 2026 | Young David Pres. Research & Development, Director | Bought | 2,531 | $1.93 | $4,885 |
| 15 June 2026 | Young David Pres. Research & Development, Director | Bought | 2,067 | $2.22 | $4,589 |
| 15 June 2026 | SKIBSTED RUSSELL Chief Financial Officer | Bought | 2,654 | $2.22 | $5,892 |
| 15 June 2026 | Ng George K Chief Executive Officer, Director | Bought | 2,465 | $2.22 | $5,472 |
| 15 June 2026 | Lin Patrick Chief Business - Strategy Off | Bought | 1,831 | $2.22 | $4,065 |
| 15 June 2026 | Guy Wendy Chief Administrative Officer | Bought | 2,118 | $2.22 | $4,702 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
1 serious warning sign in Processa Pharmaceuticals’ filings.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 18 Mar 2026, plus the 10-Q filed 13 Nov 2026 and 6 later 8-Ks.
Doubt it can keep going
SeriousThe company or its auditor warned it may not have enough money to last the next year.
“As a result, we concluded that the proceeds received from the private placement financing cannot be relied upon to mitigate the conditions that raised substantial doubt because the availability of those proceeds is subject to conditions that are not entirely within our control.”
Show the full paragraph
The Series A Preferred Stock are convertible into shares of common stock, subject to receiving stockholder approval of the issuance of shares of common stock upon conversion of Series A Preferred Stock and exercise of the Assumed Options (see Note 2 for additional information on the planned proposals for the stockholder meeting). Under the terms of the Certificate of Designation of Preferences, Rights and Limitations of the Series A Preferred Stock (the “Certificate of Designation”), if we fail to deliver to the holder of the Series A Preferred Stock shares of our common stock underlying such shares of Series A Preferred Stock at any time nine months after the initial issuance of the Series A Preferred Stock, holders of the Series A Preferred Stock are entitled to require us to make cash payments by wire transfer of immediately available funds equal to the Fair Value (as defined in the Certificate of Designation) of such undelivered shares, subject to the applicable conversion-notice and delivery requirements, exceptions and availability of legally available funds. As a result, we concluded that the proceeds received from the private placement financing cannot be relied upon to mitigate the conditions that raised substantial doubt because the availability of those proceeds is subject to conditions that are not entirely within our control. Our plan to address this potential cash-settlement obligation is to obtain the requisite stockholder approval at a meeting expected to take place in the first quarter of 2027 and thereafter complete the conversion of the Series A Preferred Stock and delivery of the underlying common stock, subject to applicable beneficial ownership limitations. Accordingly, we concluded that substantial doubt about our ability to continue as a going concern continues to exist within one year after the date these financial statements are available to be issued.
From the 10-Q filed 13 November 2026, Part I, Item 1. Financial Statements. Read it in the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.